HR and breast cancer: The overall rate of pCR, which is defined as no pathologic evidence of residual invasive cancer in the breast and sampled regional lymph nodes, was 41.7% (45.5% in patients with TNBC, 37.5% for patients with HR+/HER- BC, 66.7% in patients with HR−/HER2+ BC, and 0% for patients with HR+ HER2+ BC).